Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Published:2014-05-29 Issue:22 Volume:370 Page:2071-2082
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Richeldi Luca,du Bois Roland M.,Raghu Ganesh,Azuma Arata,Brown Kevin K.,Costabel Ulrich,Cottin Vincent,Flaherty Kevin R.,Hansell David M.,Inoue Yoshikazu,Kim Dong Soon,Kolb Martin,Nicholson Andrew G.,Noble Paul W.,Selman Moisés,Taniguchi Hiroyuki,Brun Michèle,Le Maulf Florence,Girard Mannaïg,Stowasser Susanne,Schlenker-Herceg Rozsa,Disse Bernd,Collard Harold R.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402584

Cited by 3512 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Idiopathic pulmonary fibrosis with a typical usual interstitial pneumonia pattern on chest high-resolution computed tomography;Rare and Interstitial Lung Diseases;2025

2. Therapeutic potential of human stem cell-derived extracellular vesicles in idiopathic pulmonary fibrosis;Extracellular Vesicle;2024-12

3. “Bubbly lung”, a honeycombing variant with more favorable outcome;Respiratory Investigation;2024-11

4. A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD;Heart & Lung;2024-11

5. Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study;Respiratory Medicine;2024-11